Endocrine System Diseases  >>  Tekturna (aliskiren)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tekturna (aliskiren) / PDL
NCT00097955: Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Completed
2
496
US, Canada, Europe, RoW
aliskiren
Novartis Pharmaceuticals
Diabetic Nephropathy
04/07
04/07
NCT00461136 / 2005-000361-19: Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes

Completed
1/2
18
Europe
Aliskiren
Novartis
Diabetes Type 2
11/06
11/06
NCT00464776 / 2005-000286-19: Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy

Completed
1/2
26
Europe
Aliskiren, SPP100
Novartis
Diabetes Mellitus, Type 2
04/08
 

Download Options